Lung Cancer Therapeutics Market Is Expected To Exhibit Significant Growth Over 2031

The global lung cancer therapeutics market is anticipated to grow at a CAGR of 8.7% during the forecast period. The key factor to drive the market growth is the rising number of smokers in various countries that is the leading risk factor for lung cancer. According to the American Cancer Society, smoking is thought to be responsible for approximately 80% of lung cancer deaths, and this estimate is likely to be even higher in the case of small cell lung cancer (SCLC). Furthermore, according to Macmillan Cancer Support, tobacco use is the leading cause of lung cancer and the leading risk factor. This includes using tobacco products such as cigars, cigarettes, and others. The more you smoke, the greater the risk is associated. Smoker or ex-smokers account for approximately 9 out of 10 lung cancer cases (90%). Moreover, people who do not smoke can also develop lung cancer, but their chances are much lower. One out of every 10 people who develop lung cancer (10%) has never smoked.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-therapeutics-market

Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in January 2019, Eli Lilly and Co announced that that the U.S. Food and Drug Administration (FDA) has approved its new indication for ALIMTA that is in combination with KEYTRUDA, produced and commercialized by Merck and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) that have no ALK genomic tumor aberrations. This new indication demonstrates Lilly's ongoing commitment to providing effective treatment options that can make a significant difference in the lives of people living with lung cancer.

Global Lung Cancer Therapeutics Market Report Segment

By Drugs

• Platinol
• Taxol
• Gemzar
• Alimta
• Others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori)

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Others

By End-User

• Multispeciality Hospitals
• Cancer Research Centers

A full report of Lung Cancer Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/lung-cancer-therapeutics-market

Lung Cancer Therapeutics Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Abbvie Inc.
• Achieve Life Sciences, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Astellas Pharma Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Celldex Therapeutics, Inc
• Eisai Co Ltd
• Eli Lilly and Co.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.